Liver Fat Articles & Analysis
11 news found
Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver CongressTM 2022, to be held in London, UK on June 22-26, 2022. ...
Hepatic steatosis can progress to nonalcoholic steatohepatitis (NASH) with fibrosis, and NASH-associated liver failure is one of the leading causes of liver transplant in the United States. ...
The 12-week Phase 1b NAFLD trial is designed to assess the effects of pemvidutide on liver fat in subjects with obesity or overweight and liver fat content of 10% or greater as measured by MRI-PDFF. ...
” HemoShear’s REVEAL-Tx™ platform has been utilized to create a model of NASH that recapitulates hallmark features of liver fat build up, increased cell stress and inflammation, and extracellular matrix signaling that was published in the Journal of Clinical Investigation Insight. In addition, Nature Scientific Reports published the ...
When measuring fatty liver disease in obese patients, a greater imaging depth (below subcutaneous fat and the liver capsule) results in a more accurate liver health assessment. ...
With 100 million Americans affected by fatty liver disease, one-fifth will progress to a more severe form of the condition and are at further risk of developing cirrhosis and liver cancer. ...
In addition, patients showed an average of 31% reduction in liver fat along with significant reductions in body weight. There were no procedure-related serious adverse events. ...
Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date. LEXINGTON, Mass., August 6, 2020 – Fractyl Laboratories Inc. ...
In addition to the glycemic benefits observed in type 2 diabetes in earlier studies, there was also significant improvement in liver disease parameters, including significant reduction in liver fat, and lipid profiles. ...
Non-Alcoholic Steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NAFLD is as high as one billion and is the most common cause of chronic liver disease, affecting between 80 and 100 million in the U.S., among whom nearly 25% progress to NASH. NASH is characterized by the presence of an abnormal ...
People develop NASH when early liver disease, characterized by too much fat in the liver, is exacerbated by inflammation. ...